Acute Leukemias: From diagnosis to monitoring

The BD OneFlow™ AML/MDS Panel is intended for qualitative flow-cytometric immunophenotyping of mature and immature hematopoietic cells populations (lymphoid and myeloid lineages) in bone marrow and peripheral blood. It is used as an aid in the differential diagnosis of hematologically abnormal patients, having or suspected of having, acute myeloid leukemia, acute leukemia of ambiguous lineage, mixed phenotype acute leukemia, myelodysplastic syndrome, or myelodysplastic/myeloproliferative neoplasms.

Multiparametric flow-cytometry (MFC) is a diagnostic technique that allows a fluorescence-based assessment of surface, cytoplasmic and nuclear antigen expression on a suspension of blood, bone marrow or solid-tissue cells. According to the recent diagnostic guidelines (WHO 5^th and ICC) MFC has a fundamental role in lineage assessment in acute leukemia. Furthermore, technical advancement in the field allows to routinely apply multi-color panels that allow to dissect the biological heterogeneity of the leukemic clone also in lineage-ambiguous or undifferentiated leukemias.

Besides having a key role in lineage assessment, MFC has a fundamental role in response assessment by the evaluation of Measurable Residual Disease (MRD). MRD has emerged as a powerful prognostic biomarker in acute leukemia, deeply influencing risk stratification, post-remission management, and transplant decision-making. Advances in MFC have increasingly enabled sensitive detection of leukemic persistence, uncovering disease dynamics that are imperceptible with conventional morphology. Despite these technological developments, important challenges remain regarding standardization, interpretation, timing of assessments and integration of MRD into therapeutic algorithms across diverse patient populations.

By the end of this webinar, participants will be able to understand:

1. The core principles of MFC and its role in assessing antigen expression in hematologic malignancies.
2. The WHO 5th Edition and ICC guidelines and how MFC supports accurate lineage assignment in acute leukemia.
3. The benefits of modern multi-color MFC panels for characterizing leukemic heterogeneity, including lineage ambiguous cases.
4. The significance of measurable residual disease (MRD) and how MFC enhances detection of leukemic persistence.

The BD OneFlow™ AML/MDS Panel has not been tested on specimens from patients with minimal residual disease (MRD).

The BD OneFlow™ LST, BD OneFlow™ B-CLPD T1, BD OneFlow™ PCST, BD OneFlow™ PCD, BD OneFlow™ ALOT, BD OneFlow™ BCP-ALL T1, BD OneFlow™ AML T1, BD OneFlow™ AML T2, BD OneFlow™ AML T3, BD OneFlow™ AML T4 are in vitro diagnostic medical devices bearing a CE mark and are CE certified by BSI Group The Netherlands B. V. (Notified Body Number = 2797) The BD flow cytometers are Class 1 Laser Product.

EuroFlow is a trademark of the EuroFlow Consortium.

The EuroFlow™ antibody panels are property of the EuroFlow Consortium and can not be reproduced or published without prior written permission by the EuroFlow coordinator

(www.euroflow.org).